The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Genetically modified immunosuppresants. Buy the report here.

Smarter leaders trust GlobalData

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Genetically modified immunosuppressants is a key innovation area in pharmaceuticals

Genetically modified immunosuppressants are drugs that are genetically modified to suppress the immune system and decrease the body's ability to reject a transplanted organ.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 50 companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of genetically modified immunosuppressants.

Key players in genetically modified immunosuppressants – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to genetically modified immunosuppressants

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
Takeda Pharmaceutical 137 Unlock Company Profile
Sangamo Therapeutics 104 Unlock Company Profile
Pluri 93 Unlock Company Profile
Bristol-Myers Squibb 73 Unlock Company Profile
Mesoblast 66 Unlock Company Profile
Athersys 39 Unlock Company Profile
Rubius Therapeutics 33 Unlock Company Profile
Celularity 32 Unlock Company Profile
Johnson & Johnson 28 Unlock Company Profile
Memorial Sloan Kettering Cancer Center 28 Unlock Company Profile
St. Jude Children’s Research Hospital 26 Unlock Company Profile
Daiichi Sankyo 22 Unlock Company Profile
Selecta Biosciences 22 Unlock Company Profile
SBI Holdings 22 Unlock Company Profile
Light Chain Bioscience 20 Unlock Company Profile
Hadasit Bio-Holdings 19 Unlock Company Profile
KYORIN Holdings 18 Unlock Company Profile
LG 17 Unlock Company Profile
Transimmune 16 Unlock Company Profile
Spanish National Research Council 16 Unlock Company Profile
Smith & Nephew 15 Unlock Company Profile
Priothera 14 Unlock Company Profile
Compugen 14 Unlock Company Profile
F. Hoffmann-La Roche 14 Unlock Company Profile
Garnet BioTherapeutics 14 Unlock Company Profile
Orbsen Therapeutics 13 Unlock Company Profile
Nippon Kayaku 13 Unlock Company Profile
Fred Hutchinson Cancer Research Center 12 Unlock Company Profile
Showa Denko 12 Unlock Company Profile
ReNeuron Group 12 Unlock Company Profile
Myelin Repair Foundation 12 Unlock Company Profile
PPF Group 11 Unlock Company Profile
General Hospital 10 Unlock Company Profile
Charles River Laboratories International 10 Unlock Company Profile
Erasmus MC 10 Unlock Company Profile
ImCyse 10 Unlock Company Profile
ImmuneMed 9 Unlock Company Profile
CoImmune 9 Unlock Company Profile
Massachusetts General Hospital 8 Unlock Company Profile
Stichting Sanquin Bloedvoorziening 7 Unlock Company Profile
Tocagen 7 Unlock Company Profile
Nagase & Co 7 Unlock Company Profile
UK Research and Innovation 7 Unlock Company Profile
CELLnLIFE 6 Unlock Company Profile
BioNTech 6 Unlock Company Profile
VivoscriptInc 6 Unlock Company Profile
Medeor Therapeutics 5 Unlock Company Profile
Enzo Biochem 5 Unlock Company Profile
Riken 5 Unlock Company Profile
Bambino Gesu Children’s Hospital 5 Unlock Company Profile

Source: GlobalData Patent Analytics

Takeda is the leading patent holder for genetically modified immunosuppressants. The company has various immunosuppressants such as mezagitamab, which is currentlyin late-stage clinicaldevelopment. Monoclonal antibodies constitute the majority of products in its pipeline with immunosuppressive activity.

In terms of application diversity, Hadasit Bio-Holdings is the top company, followed by CELLnLIFE and BioNTech. By means of geographic reach, Myelin Repair Foundation holds the top position, while ReNeuron Group and ImCyse are in the second and third positions, respectively. 

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.